Evaluation Of The Efficacy Of Recombinant Human Growth Hormone In The Treatment Of Achondroplasia

Objective: To evaluate the therapeutic effect of recombinant human growth hormone(rh GH)on children with achondroplasia.Methods: From January 1,2015 to March 1,2020,7 children with achondroplasia diagnosed and treated in the pediatric endocrinology and genetic metabolic disease professional group of the First Affiliated Hospital of Xinjiang Medical University were selected.The annual growth rate,bone age,age,thyroid function,blood glucose,insulin,glycosylated hemoglobin,C-peptide and vitamin D levels of children with ACH were analyzed retrospectively.Results:(1)the growth rate of ACH children treated with rh GH in one year was significantly higher than that before treatment;(2)Compared with children of the same age and sex,the variation range of height standard deviation is less than 1 SDS,and the overall fluctuation is between 0.33 SD and0.85 SD,but there is catch-up;(3)However,the height and bone age of untreated children with ACH are more and more behind the same age children of the same sex,so the evaluation is effective.Conclusion: The growth and development of children with ACH after rh GH treatment is better than before,and the treatment of rh GH in children with ACH has obvious individual differences,early diagnosis and treatment of the disease can effectively improve the prognosis.